Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL11901716

N.Nc1ccc(F)cc1-c1ccccc1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
HSD17B10 Q99714 1/20 0.52
KEAP1 Q14145 1/20 0.42
ADORA1 P30542 3/20 0.41
ADORA2A P29274 3/20 0.41
TAAR1 Q96RJ0 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
PTK2B Q14289 1/20 0.39
METAP2 P50579 1/20 0.39
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38
BACE1 P56817 1/20 0.38
MAPT P10636 2/20 0.38
HDAC1 Q13547 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3793169 0.98 ALDH1A1 (0.54) ALDH1A1HSD17B10KEAP1ADORA1ADORA2A
SCHEMBL29492484 0.98 ALDH1A1 (0.54) ALDH1A1HSD17B10KEAP1ADORA1ADORA2A
Hydrochloric Acid SCHEMBL9311952 0.96 ALDH1A1 (0.52) ALDH1A1HSD17B10KEAP1ADORA1ADORA2A
SCHEMBL6557724 0.85 ALDH1A1 (0.52) ALDH1A1KEAP1TAAR1CYP1A2CYP2C9
SCHEMBL3789841 0.81 TAAR1 (0.50) ALDH1A1HSD17B10KEAP1TAAR1MAPT
SCHEMBL3785218 0.81 ALDH1A1 (0.54) ALDH1A1HSD17B10KEAP1ADORA1ADORA2A
SCHEMBL3783916 0.80 MAOA (0.47) ALDH1A1TAAR1MKNK1MKNK2MAPT
SCHEMBL29901139 0.79 ALDH1A1 (0.62) ALDH1A1KEAP1CYP1A2BACE1HDAC1
SCHEMBL3787023 0.78 ALDH1A1 (0.59) ALDH1A1HSD17B10KEAP1ADORA2ACYP1A2
SCHEMBL21088010 0.78 ALDH1A1 (0.50) ALDH1A1KEAP1TAAR1CYP1A2BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 ALDH1A1 1680/4885HSD17B10 664/4885KEAP1 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.